BRPI0920108A2 - peptídomimético cíclico contendo argina, glicina, ácido aspártico (rgd), conjugado de peptidomimético cíclico contendo rgd, composição farmacêutica, conjugado e uso do mesmo. - Google Patents
peptídomimético cíclico contendo argina, glicina, ácido aspártico (rgd), conjugado de peptidomimético cíclico contendo rgd, composição farmacêutica, conjugado e uso do mesmo.Info
- Publication number
- BRPI0920108A2 BRPI0920108A2 BRPI0920108A BRPI0920108A BRPI0920108A2 BR PI0920108 A2 BRPI0920108 A2 BR PI0920108A2 BR PI0920108 A BRPI0920108 A BR PI0920108A BR PI0920108 A BRPI0920108 A BR PI0920108A BR PI0920108 A2 BRPI0920108 A2 BR PI0920108A2
- Authority
- BR
- Brazil
- Prior art keywords
- rgd
- conjugate
- cyclic peptidomimetic
- argin
- glycine
- Prior art date
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title 2
- 125000004122 cyclic group Chemical group 0.000 title 2
- 239000000816 peptidomimetic Substances 0.000 title 2
- 239000004471 Glycine Substances 0.000 title 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 title 1
- 235000003704 aspartic acid Nutrition 0.000 title 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10795208P | 2008-10-23 | 2008-10-23 | |
| PCT/IL2009/000995 WO2010046900A2 (en) | 2008-10-23 | 2009-10-22 | Rgd-containing peptidomimetics and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0920108A2 true BRPI0920108A2 (pt) | 2016-12-13 |
Family
ID=42077845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0920108A BRPI0920108A2 (pt) | 2008-10-23 | 2009-10-22 | peptídomimético cíclico contendo argina, glicina, ácido aspártico (rgd), conjugado de peptidomimético cíclico contendo rgd, composição farmacêutica, conjugado e uso do mesmo. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8673270B2 (pt) |
| EP (1) | EP2358737B1 (pt) |
| JP (1) | JP5773495B2 (pt) |
| CN (1) | CN102264756B (pt) |
| AU (1) | AU2009305893B2 (pt) |
| BR (1) | BRPI0920108A2 (pt) |
| CA (1) | CA2741207C (pt) |
| DK (1) | DK2358737T3 (pt) |
| ES (1) | ES2627377T3 (pt) |
| HU (1) | HUE033118T2 (pt) |
| LT (1) | LT2358737T (pt) |
| MX (1) | MX2011004252A (pt) |
| PL (1) | PL2358737T3 (pt) |
| PT (1) | PT2358737T (pt) |
| RU (1) | RU2519736C2 (pt) |
| WO (1) | WO2010046900A2 (pt) |
| ZA (1) | ZA201103712B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20050328A1 (it) | 2005-03-03 | 2006-09-04 | Univ Degli Studi Milano | Composti peptidomimetrici e preparazione di derivati biologicamente attivi |
| WO2015089268A1 (en) * | 2013-12-11 | 2015-06-18 | University Of Massachusetts | Compositions and methods for treating disease using salmonella t3ss effector protein (sipa) |
| GB201402267D0 (en) * | 2014-02-10 | 2014-03-26 | Cambridge Entpr Ltd | Antibacterial agents |
| CN104004514B (zh) * | 2014-06-06 | 2015-07-29 | 福建师范大学 | 一种检测三价铋离子的对称双罗丹明荧光探针及制备方法和用途 |
| CN105859832A (zh) * | 2015-01-19 | 2016-08-17 | 复旦大学 | 以rgd为活性中心的多肽及其在制备治疗缺血性脑卒中靶向药物中的应用 |
| CN106518965A (zh) * | 2015-09-10 | 2017-03-22 | 华东理工大学 | 对溶血磷脂酸特异性识别的多肽探针及其制备与应用 |
| BR112018070847A2 (pt) | 2016-04-10 | 2019-02-05 | Memorial Sloan Kettering Cancer Center | terapias combinadas para tratamento de câncer compreendendo um derivado de bacterioclorofila |
| CN105820215A (zh) * | 2016-05-09 | 2016-08-03 | 中国人民解放军第二军医大学 | 一种高效合成Stylissatin A天然环七肽的制备方法 |
| US10933134B2 (en) | 2017-03-16 | 2021-03-02 | Memorial Sloan Kettering Cancer Center | Combination therapies for treatment of cancer |
| US11965041B2 (en) | 2017-09-19 | 2024-04-23 | Technische Universitaet Muenchen | N-methylated cyclic peptides and their prodrugs |
| WO2019058367A1 (en) * | 2017-09-19 | 2019-03-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | LIPOPHILIC PRODRUGS BASED ON PEPTIDES |
| CN109091683B (zh) * | 2018-08-10 | 2019-10-18 | 北京大学 | 一种用于整合素αvβ6靶向的环状多肽放射性药物及其制备方法 |
| CN108948142B (zh) * | 2018-09-04 | 2022-02-22 | 川北医学院 | 一种靶向肿瘤细胞及新生血管的荧光探针及其制备方法 |
| JP2022507958A (ja) * | 2018-11-27 | 2022-01-18 | ノバルティス アーゲー | 代謝障害の治療用のプロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）阻害薬としての環状四量体化合物 |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| WO2020110011A1 (en) | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
| CN113748125A (zh) * | 2019-03-19 | 2021-12-03 | 恩泽生物科学有限公司 | 胰高血糖素样肽-1(glp-1)受体激动剂及其类似物的制备方法 |
| RU2735649C1 (ru) * | 2019-10-08 | 2020-11-05 | Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук | Комбинированные покрытия на основе биологически активных rgd-функционализированных бифосфонатов аминокислот и пэо-подслоя для титана |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4310643A1 (de) * | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| US5770565A (en) * | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
| EP0927045B1 (en) * | 1996-09-10 | 2005-12-14 | The Burnham Institute | Tumor homing molecules, conjugates derived therefrom, and methods of using same |
| US6451972B1 (en) * | 1998-11-16 | 2002-09-17 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
| ES2366775T3 (es) * | 2001-04-24 | 2011-10-25 | Merck Patent Gmbh | POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa). |
| CA2661319C (en) | 2006-08-23 | 2015-12-01 | Yeda Research And Development Co. Ltd | Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses |
-
2009
- 2009-10-22 RU RU2011120332/04A patent/RU2519736C2/ru active
- 2009-10-22 DK DK09774982.4T patent/DK2358737T3/en active
- 2009-10-22 MX MX2011004252A patent/MX2011004252A/es active IP Right Grant
- 2009-10-22 JP JP2011532768A patent/JP5773495B2/ja not_active Expired - Fee Related
- 2009-10-22 CN CN200980152371.9A patent/CN102264756B/zh not_active Expired - Fee Related
- 2009-10-22 PT PT97749824T patent/PT2358737T/pt unknown
- 2009-10-22 ES ES09774982.4T patent/ES2627377T3/es active Active
- 2009-10-22 CA CA2741207A patent/CA2741207C/en active Active
- 2009-10-22 LT LTEP09774982.4T patent/LT2358737T/lt unknown
- 2009-10-22 WO PCT/IL2009/000995 patent/WO2010046900A2/en active Application Filing
- 2009-10-22 BR BRPI0920108A patent/BRPI0920108A2/pt not_active IP Right Cessation
- 2009-10-22 US US13/125,371 patent/US8673270B2/en active Active
- 2009-10-22 PL PL09774982T patent/PL2358737T3/pl unknown
- 2009-10-22 EP EP09774982.4A patent/EP2358737B1/en not_active Not-in-force
- 2009-10-22 AU AU2009305893A patent/AU2009305893B2/en not_active Ceased
- 2009-10-22 HU HUE09774982A patent/HUE033118T2/en unknown
-
2011
- 2011-05-20 ZA ZA2011/03712A patent/ZA201103712B/en unknown
-
2014
- 2014-02-07 US US14/175,302 patent/US9119885B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8673270B2 (en) | 2014-03-18 |
| ES2627377T3 (es) | 2017-07-27 |
| US20110250144A1 (en) | 2011-10-13 |
| EP2358737B1 (en) | 2017-03-01 |
| US9119885B2 (en) | 2015-09-01 |
| CA2741207A1 (en) | 2010-04-29 |
| RU2011120332A (ru) | 2012-11-27 |
| JP5773495B2 (ja) | 2015-09-02 |
| US20140154181A1 (en) | 2014-06-05 |
| ZA201103712B (en) | 2013-03-27 |
| CN102264756A (zh) | 2011-11-30 |
| EP2358737A2 (en) | 2011-08-24 |
| CN102264756B (zh) | 2014-08-06 |
| WO2010046900A3 (en) | 2010-08-19 |
| WO2010046900A2 (en) | 2010-04-29 |
| PT2358737T (pt) | 2017-06-12 |
| LT2358737T (lt) | 2017-06-26 |
| DK2358737T3 (en) | 2017-06-19 |
| RU2519736C2 (ru) | 2014-06-20 |
| PL2358737T3 (pl) | 2017-10-31 |
| CA2741207C (en) | 2017-03-21 |
| MX2011004252A (es) | 2012-01-27 |
| HUE033118T2 (en) | 2017-11-28 |
| AU2009305893A1 (en) | 2010-04-29 |
| AU2009305893B2 (en) | 2014-03-27 |
| JP2012506419A (ja) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0920108A2 (pt) | peptídomimético cíclico contendo argina, glicina, ácido aspártico (rgd), conjugado de peptidomimético cíclico contendo rgd, composição farmacêutica, conjugado e uso do mesmo. | |
| IL244812A0 (en) | 6-ethyl, 23-methyl-cholic acid, its conjugates with glycine and taurine and pharmaceutical preparations containing them | |
| BRPI0908097A2 (pt) | uso de pelo menos um composto, peptídeo, e, formulação farmacêutica. | |
| BRPI0910557A2 (pt) | composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso. | |
| BRPI0909084A2 (pt) | Composição líquida, e, composto de peptídeo. | |
| BRPI0815709A2 (pt) | composro, composição farmacêutica, e, uso de um composto. | |
| BRPI0915137A2 (pt) | uso de pelo menos um composto, peptídeo, e, formulação farmacêutica | |
| BR112013016772A2 (pt) | composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado | |
| BRPI0918502A2 (pt) | aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos | |
| BRPI0809366A8 (pt) | polipeptídeos interligados | |
| BRPI1007018A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BRPI0618904A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| BR112012003800A2 (pt) | composição, peptídeo, e formulação farmacêutica. | |
| BRPI1008906A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
| EA201101220A1 (ru) | Диспергируемый в воде гранулированный состав | |
| BRPI0915136A2 (pt) | uso de pelo menos um composto, peptídeo, e, formulação farmacêutica | |
| BRPI0915552A2 (pt) | derivados de ciclosporina, seu uso e sua composição farmacêutica | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| BRPI0912717A2 (pt) | Composição farmacêutica, e, uso de 5-azacitidina | |
| BRPI0924183A2 (pt) | inibidores de proteína quinase, formas cristalinas, formulações farmacêuticas e uso | |
| EP2305214A4 (en) | NEW MOLECULAR ARRANGEMENT, MOLECULAR PROBE FOR MOLECULAR IMAGING AND MOLECULAR PROBE FOR A DRUG DELIVERY SYSTEM, AND MOLECULAR IMAGING SYSTEM AND DRUG DISPENSING SYSTEM | |
| BRPI0907562A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1014034A2 (pt) | formulação e seu uso, composição, solução injetável e kit. | |
| BRPI0907453A2 (pt) | Compostos, uso e preparação dos mesmos | |
| BRPI0812134A2 (pt) | Anatagonistas de cxcr4 de peptídio cíclico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: STEBA BIOTECH S.A. (LU) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2641 DE 17-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |